# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-26-036629
Filing Date
2026-03-31
Accepted
2026-03-30 20:07:41
Documents
76
Period of Report
2025-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | ANNUAL REPORT | ea0283146-10k_ostherap.htm iXBRL | 10-K | 1535123
2 | DESCRIPTION OF REGISTERED SECURITIES | ea028314601ex4-9.htm | EX-4.9 | 40730
3 | LIST OF SUBSIDIARIES OF THE REGISTRANT | ea028314601ex21-1.htm | EX-21.1 | 2055
4 | CONSENT OF MALONEBAILEY, LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | ea028314601ex23-1.htm | EX-23.1 | 1922
5 | CERTIFICATION | ea028314601ex31-1.htm | EX-31.1 | 9974
6 | CERTIFICATION | ea028314601ex31-2.htm | EX-31.2 | 9902
7 | CERTIFICATION | ea028314601ex32-1.htm | EX-32.1 | 4840
8 | CERTIFICATION | ea028314601ex32-2.htm | EX-32.2 | 4859
9 | GRAPHIC | ea028314601_img1.jpg | GRAPHIC | 142334
10 | GRAPHIC | ea028314601_img2.jpg | GRAPHIC | 61310
11 | GRAPHIC | ea028314601_ex21-1img1.jpg | GRAPHIC | 19295
| Complete submission text file | 0001213900-26-036629.txt |  | 7993473

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
12 | XBRL SCHEMA FILE | osti-20251231.xsd | EX-101.SCH | 67840
13 | XBRL CALCULATION FILE | osti-20251231_cal.xml | EX-101.CAL | 40075
14 | XBRL DEFINITION FILE | osti-20251231_def.xml | EX-101.DEF | 338885
15 | XBRL LABEL FILE | osti-20251231_lab.xml | EX-101.LAB | 625375
16 | XBRL PRESENTATION FILE | osti-20251231_pre.xml | EX-101.PRE | 364546
79 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0283146-10k_ostherap_htm.xml | XML | 635004

Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Filer) CIK: 0001795091 (see all company filings)

EIN.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-42195 | Film No.: 26816200
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)